- Home
- TXMD vs BHAT Comparison
TXMD vs BHAT Comparison
Compare TXMD & BHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- BHAT
- Stock Information
- Founded
- TXMD 2008
- BHAT 2010
- Country
- TXMD United States
- BHAT China
- Employees
- TXMD N/A
- BHAT N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- BHAT Recreational Games/Products/Toys
- Sector
- TXMD Health Care
- BHAT Consumer Discretionary
- Exchange
- TXMD Nasdaq
- BHAT Nasdaq
- Market Cap
- TXMD 12.7M
- BHAT 12.7M
- IPO Year
- TXMD N/A
- BHAT 2019
- Fundamental
- Price
- TXMD $1.17
- BHAT $1.64
- Analyst Decision
- TXMD
- BHAT
- Analyst Count
- TXMD 0
- BHAT 0
- Target Price
- TXMD N/A
- BHAT N/A
- AVG Volume (30 Days)
- TXMD 23.3K
- BHAT 72.9K
- Earning Date
- TXMD 08-12-2025
- BHAT 04-30-2025
- Dividend Yield
- TXMD N/A
- BHAT N/A
- EPS Growth
- TXMD N/A
- BHAT N/A
- EPS
- TXMD N/A
- BHAT N/A
- Revenue
- TXMD $1,841,000.00
- BHAT $18,724,190.00
- Revenue This Year
- TXMD $427.09
- BHAT N/A
- Revenue Next Year
- TXMD N/A
- BHAT N/A
- P/E Ratio
- TXMD N/A
- BHAT N/A
- Revenue Growth
- TXMD 53.55
- BHAT N/A
- 52 Week Low
- TXMD $0.70
- BHAT $1.56
- 52 Week High
- TXMD $2.44
- BHAT $72.80
- Technical
- Relative Strength Index (RSI)
- TXMD 54.93
- BHAT 38.24
- Support Level
- TXMD $1.06
- BHAT $1.56
- Resistance Level
- TXMD $1.12
- BHAT $1.78
- Average True Range (ATR)
- TXMD 0.04
- BHAT 0.08
- MACD
- TXMD 0.01
- BHAT -0.01
- Stochastic Oscillator
- TXMD 73.27
- BHAT 25.32
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About BHAT Blue Hat Interactive Entertainment Technology
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.